Experts will present practical approaches for studying GLP-1 therapeutics, metabolic disease, New Approach Methodologies (NAMs), and complex drug modalities

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will share new research and practical approaches to help drug developers select fit-for-purpose models for increasingly complex therapeutic programs at several scientific events this fall. Through presentations, posters, and an upcoming webinar, BioIVT experts will address emerging questions related to GLP-1 therapeutics, metabolic disease, New Approach Methodologies (NAMs), and targeted protein degraders.

A focal point of BioIVT’s fall program will be the 27^th North American ISSX Meeting, which takes place October 11-14 in San Francisco, CA. Through a breakfast symposium and three scientific posters, BioIVT scientists will share research on complex peptide metabolism, low-turnover reaction phenotyping, and translational models of metabolic disease. Attendees can also visit booth #504 to learn about BioIVT’s ADME research products and consulting support.

Joanna Barbara, PhD, General Manager of ADME Services at BioIVT, will lead the breakfast symposium, “Advancing In Vitro Approaches to Explore Tissue Metabolism of Complex Peptide Therapeutics: A GLP-1 Case Study,” on October 13 from 7:15-8:15 am.

The following three posters will also be presented at ISSX:

• Poster P79: “Development of a Bioinformatics-Guided Pan-UGT1A siRNA for Low-Turnover Compound Reaction Phenotyping in HEPATOPAC®,” presented by Christian Smith, Scientist I, R&D, on October 13 from 12-12:45 pm
• Poster P58: “Establishing the Translational Relevance of Modeling MASLD in HEPATOPAC Through Proteomic Profiling,” presented by Karissa Cottier, PhD, Manager of R&D, on October 13 from 12:45-1:30 pm
• Poster P126: “Characterization of Lipid-Modified Peptide GLP-1 Receptor Agonist Metabolism in Sandwich-Cultured Hepatocytes Using Extended In Vitro Incubations,” presented by Seema Muranjan, MS, Director of BioIVT Kansas City Facilities and Instrumentation, on October 14 from 12:45-1:30 pm

BioIVT will extend the discussion around GLP-1 therapeutics and metabolic disease through a live webinar, “Advancing Metabolic Disease Drug Development: Translational Models and a GLP-1 Receptor Agonist Metabolism Case Study,” on October 22 at 11 am ET. Dr. Joanna Barbara and Brian Ogilvie, PhD, Vice President of Scientific Consulting at BioIVT, will discuss the biological relationships among obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), along with how disease-state biospecimens, primary cells, subcellular fractions, HEPATOPAC, and in vitro ADME services can support metabolic disease programs.

“As therapies become more complex, researchers need the right test systems to answer specific questions,” said Dr. Joanna Barbara. “Across these fall events, our experts will share research and insights to help scientists select the appropriate models and experimental designs to generate data that can ultimately better inform drug development.”

Throughout the fall, BioIVT will highlight its expertise at several additional scientific events, including:

• BIOSPAIN 2026, September 29-October 1 in Bilbao, Spain, booth #87. BeCytes, a BioIVT company, is a sponsor of the event. Natalia Sánchez, PhD, R&D Director, will participate in the roundtable, “New Approach Methodologies (NAMs): Accelerating Safer, Smarter and More Human-Relevant Innovation in Drug and Chemical Development,” on September 30 from 12:15-1 pm
• DMDG-GMP-SPS Joint Meeting, October 5-7 in Prague, Czechia, table #18. Dr. Joanna Barbara will present the poster, “In Vitro Lysosomal Catabolism of GLP-1 Peptide Therapeutics: A Human versus Rat Species Comparison,” examining the metabolism of two GLP-1 agonists in human liver lysosomes and rat liver tritosomes
• AAPS PharmSci 360, October 25-28 in New Orleans, LA, booth #1107. Kent Grindstaff, PhD, Consulting Director at BioIVT, will moderate the symposium, “Model-Informed Innovation: Integrating NAMs Across Translational Workflows,” on October 27 from 9-11 am. The symposium will feature presentations on quantitative systems toxicology and microphysiological systems, AAV efficacy and toxicity, preclinical testing, and whole blood NAMs for immunotoxicology
• 9th TPD and Induced Proximity Summit, October 26-29 in Boston, MA. Tina Mueller, PhD, Scientific Advisor for ADMET Services at BioIVT, will present “The In Vitro ADME Playbook for Protein Degraders: What’s Different?” from 1:30-2 pm

For more information about BioIVT’s upcoming fall events circuit, please visit the website here.

About BioIVT

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit www.bioivt.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260923744855/en/

“Across these fall events, our experts will share research and insights to help scientists select the appropriate models and experimental designs to generate data that can ultimately better inform drug development.”